Skip to main content
. 2021 Mar 9;144(6):1684–1696. doi: 10.1093/brain/awab088

Table 1.

Patient and control demographics

Multiple sclerosis subjects Healthy control subjects
Sex, n (male/female) 91 (35/56) 72 (29/43)
Age, years, mean ± SD 46 ± 14 36 ± 12
EDSS score, median (range) 2.5 (0–8)
Disease course, RR/PMS 62/29
Disease-modifying therapy (n) Untreated (10)
Interferon-beta (1)
Glatiramer acetate (1)
Dimethyl fumarate (13)
Fingolimod (5)
Natalizumab (2)
Rituximab (10)
Ocrelizumab (49)

SD = standard deviation.